Endo International: Uncertain Growth Beyond 2017?

Morgan Stanley analyst David Risinger is no longer convinced that specialty drug maker Endo International (ENDP) can generate the kind of growth to justify a “buy” rating or $101 price target. Risinger downgraded the drug maker to equal weight and slashed his price target almost 16% to $85, citing growth uncertainty after 2017. With the […]